Phytonadione

TUESDAY, Dec. 9, 2025 — More parents are saying no to vitamin K shots for their newborns, and experts warn babies could be at serious risk. A study published Dec. 8 in JAMA found that refusal of vitamin K, a shot given shortly after birth to prevent dangerous bleeding, has skyrocketed in recent years. Researchers reviewed medical records for more than 5 million infants born in 403 hospitals nationwide between 2017 and 2024. In all, about 4% of babies, roughly 200,000, did not receive the shot. Refusal climbed from under 3% in 2017 to over 5% in 2024, with the sharpest increases seen after the COVID pandemic. “The increase is not surprising, but the degree to which it did increase did catch me off guard,” study author Dr. Kristan Scott , a neonatologist at Children’s Hospital of Philadelphia, told NBC News . Vitamin K is not a vaccine. It’s a supplement used to help a baby’s blood clot. Babies are born with very low vitamin K levels. Without the shot, they are more than 80 times more likely to have dangerous bleeding, according to the U.S. Centers for Disease Control and Prevention (CDC). Bleeding can happen anytime up to six months of age and may appear as bruising, internal bleeding, or, in the most severe cases, brain bleeding that can cause disability or death. “We are creating a population of newborns who are at risk of bleeding,” Scott said. “Bleeding into the brain is what we really worry about, essentially a stroke,” he explained. “That can ultimately cause death.” Experts suspect online misinformation and confusion between the vitamin K shot and vaccines may underlie the trend. “Parents are equating vitamin K injections to vaccines,” Dr. Tiffany McKee-Garrett told NBC News . She’s a neonatologist at Texas Children’s Hospital in Houston, who was not involved in the study. Some countries offer oral vitamin K instead, but doctors say it’s less reliable and in some cases, must be given multiple times. The vitamin K shot works with one dose. Vitamin K deficiency is preventable “so we shouldn’t be seeing it at all,” said Dr. Ivan Hand , neonatologist at NYC Health + Hospitals in Brooklyn. Doctors expect to see a rise in bleeding events if refusal continues. “These treatments have been so effective that people don’t understand the consequences. They have never seen babies with severe bleeding, so they think it doesn’t exist,” Hand said. “But you don’t see it because we are treating these kids.” Sources NBC News, Dec. 8, 2025

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to re-potentiate apoptosis in highly aggressive tumor type Oct. 16, 2025 -- BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that it will present two posters on its lead investigational drug BPM31510 for Glioblastoma (GBM) in collaboration with Stanford University School of Medicine and other major US cancer centers at the European Society for Medical Oncology (ESMO) Congress 2025 held from October 17 – 20 in Berlin, Germany. BPGbio has completed the phase 2b enrollment of GBM trial late August this year. Together, the presentations highlight new insights into the mitochondrial-targeting investigational therapy BPM31510, including both biomarker-driven pharmacodynamic analyses in patients with recurrent GBM and interim progress from an ongoing Phase 2 trial in newly diagnosed GBM patients. “We are excited to share the latest data from our ongoing phase 2 GBM trial at ESMO, which highlight BPM31510’s unique mechanism of reprogramming tumor metabolism to potentially improve treatment outcomes in glioblastoma, one of the most aggressive tumors” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “We appreciate our world-class partners like Stanford and Aixial Group for their continued collaboration and support as we advance BPM31510 into late-stage development.” 1. Interim Analysis of a Phase 2 Study of BPM31510 with Vitamin K in Combination with Standard Chemoradiation in Newly Diagnosed GBM Patients Collaborators: BPGbio, Stanford University, Aixial Group Design: Phase 2, single-arm, open-label trial (BPM31510IV-11; NCT04752813) testing BPM31510 with Vitamin K alongside radiotherapy and temozolomide (TMZ) in newly diagnosed GBM. Endpoints: Primary endpoints are progression-free survival at 6 months (PFS6) and 12 months (PFS12); secondary endpoints include overall survival and safety. Update: Interim PFS6 landmark data from 25 patients will be presented, assessing whether mitochondrial reprogramming by BPM31510 enhances standard-of-care efficacy 2. Biomarker Analysis of BPM31510 in Recurrent, Bevacizumab-Refractory High-Grade Glioma Shows Effects on Metabolic and Tumor Progression Markers Collaborators: BPGbio, Stanford University Insights: Phase 1 pharmacodynamic data (BPM31510IV-06; NCT03020602) Demonstrate the pharmacodynamic effect of BPM31510 on mitochondrial oxidative phosphorylation BPM31510IV is BPGbio’s lead candidate in late-stage development for aggressive solid tumors such as glioblastoma multiforme (GBM) and pancreatic cancer. Other topical and oral formulations of the investigational agent are also being developed as a potential treatment for several rare diseases including Primary CoQ10 Deficiency (PCQD). The compound has demonstrated a tolerable safety profile and is being studied for potential clinical benefits across multiple disease indications. Validated by BPGbio’s NAi Interrogative Biology platform, BPM31510 is designed to induce a hallmark shift in the tumor microenvironment (TME) by modulating mitochondrial oxidative phosphorylation in aggressive tumors, promoting programmed cell death (apoptosis). In many mitochondrial diseases, restoring CoQ10 levels can overcome the effect of mutations in genes that lead to mitochondrial dysfunction. BPM31510 has been granted Orphan Drug Designation by the FDA for GBM, pancreatic cancer, and epidermolysis bullosa (EB), as well as Rare Pediatric Disease Designation for primary CoQ10 deficiency and EB. BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 500 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. The content above comes from the network. if any infringement, please contact us to modify.